既往治疗对接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者总生存期的预后影响:WARMTH多中心研究(617试验)
WARMTH多中心回顾性分析纳入416例转移性去势抵抗性前列腺癌患者,评估既往治疗对[177Lu]Lu-PSMA-617治疗后总生存期的影响。中位OS为11.1个月,既往化疗、骨转移、肝转移及ECOG状态为总生存期较差的显著预后因素,未接受化疗者OS显著更长(14.6个月)。
要点
- 既往化疗、骨转移、肝转移及ECOG状态是多变量分析中总生存期较差的显著预后因素。
- 未接受化疗患者中位OS为14.6个月,显著长于有化疗史者。
- 既往接受一线和多线化疗患者中位OS分别为10.9个月和8.9个月。
核心结论
- 在接受[177Lu]Lu-PSMA-617治疗的多中心mCRPC分析中,未接受化疗患者的总生存期显著长于有化疗史患者。
- 多变量分析中,既往化疗、骨转移和肝转移为生存的负向预后因素,而ECOG 0-1与更长总生存期相关。
研究设计与样本
- WARMTH多中心回顾性分析(617试验),来自11家诊所的631例mCRPC患者数据。
- 纳入标准要求所有患者在[177Lu]Lu-PSMA-617治疗前至少接受过阿比特龙或恩扎卢胺。
- 患者分为三组:既往接受化疗、避免化疗、化疗禁忌。
- 最终分析纳入416例患者,中位年龄71.9岁。
主要发现
- 75.5%和26.4%患者分别有使用多西他赛和卡巴他赛的化疗史,20.4%患者曾接受Ra-223治疗。
- 中位OS为11.1个月,未接受化疗患者中位OS为14.6个月,显著更长。
- 接受一线多西他赛或两线多西他赛后卡巴他赛化疗患者的中位OS分别为10.9个月和8.9个月。
- 未化疗患者与化疗禁忌患者之间OS无差异,其他既往治疗对OS无显著影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [177Lu]Lu-PSMA-617 therapy has been the subject of controversy. Therefore, WARMTH decided to plan a multicenter retrospective analysis (the "617 trial") to evaluate response rate and OS as well as the impact of prior therapies on OS in more than 300 patients treated with 177Lu-PSMA-617. MATERIALS AND METHODS: The data of 631 metastatic CRPC (mCRPC) patients from 11 different clinics were evaluated. According to the inclusion and exclusion criteria, all patients had to have received at least abiraterone or enzalutamide prior to [177Lu]Lu-PSMA-617 therapy. The patients were divided into three groups: patients who had received prior chemotherapy, patients who avoided chemotherapy, and patients for whom a chemotherapy was contraindicated. RESULTS: The analysis included the data of 416 patients, with a median age of 71.9 years. At the time of analysis, 87 patients (20,9%) were still alive. A total of 53.6% of patients had received both abiraterone and enzalutamide; 75.5% and 26.4% had a history of chemotherapy with docetaxel and cabazitaxel, respectively. A total of 20.4% had had Ra-223. The median OS was 11.1 months. Prior chemotherapy, the existence of bone and liver metastases, as well as Eastern Cooperative Oncology Group (ECOG) status, were significant prognosticators of worse overall survival in both univariate and multivariate analyses. Patients without any prior chemotherapy showed a significantly longer OS (14.6 months). The median OS in patients who received one or two lines of chemotherapy with docetaxel or docetaxel followed by cabazitaxel, respectively, was 10.9 months and 8.9 months. There was no difference in OS between patients who had not received chemotherapy and patients for whom chemotherapy was contraindicated. The other prior therapies did not have any significant impact on OS. CONCLUSION: In the present multicenter analysis, chemotherapy-naïve mCRPC patients receiving [177Lu]Lu-PSMA-617 therapy had a significantly longer OS than patients with a history of chemotherapy. This remained independent in the multivariate analysis besides presence of bone and liver metastases as negative prognosticators for survival, whereas an ECOG of 0-1 is associated with a longer OS.
引用
- Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2020. PMID: 32383093. doi:10.1007/s00259-020-04797-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。